TABLE 1.
Clinical characteristics. Statistical comparisons were performed with linear or logistic regression as appropriate.
| Total | Non‐LBD | Diffuse / Transitional | Amygdala‐predominant | Brainstem‐ predominant | αSyn‐SAA negative | αSyn‐SAA positive | |
|---|---|---|---|---|---|---|---|
| N = 56 | N = 27 | N = 9 | N = 14 | N = 6 | N = 39 | N = 17 | |
| Demographics | |||||||
| Age at onset, y | 60 ± 9 | 59 ± 9 | 64 ± 10 | 60 ± 12 | 59 ± 5 | 59 ± 9 | 64 ± 11 |
| Age at death, y | 70 ± 9 | 69 ± 8 | 75 ± 9 | 69 ± 12 | 68 ± 6 | 68 ± 9 | 73 ± 9 |
| CSF‐autopsy interval, y | 3.8 ± 2.1 | 3.5 ± 1.4 | 3.2 ± 1.8 | 4.9 ± 2.9 † | 3.7 ± 2.9 | 3.9 ± 2.1 | 3.5 ± 2.2 |
| Female, No., % | 26, 46% | 17, 63% | 3, 33% | 5, 36% | 1, 17% | 21, 54% | 5, 29% |
| Education, y | 17 ± 3 | 17 ± 2 | 18 ± 2 | 17 ± 3 | 16 ± 3 | 17 ± 2 | 18 ± 3 |
| APOE 𝜀4 carrier, No., % | 25, 47% | 11, 42% | 2, 22% | 10, 83% † | 2, 33% | 18, 50% | 7, 41% |
| Clinical severity | |||||||
| MMSE | 21.9 ± 6.0 | 22.5 ± 6.1 | 21.8 ± 6.7 | 22.1 ± 5.1 | 19.4 ± 7.0 | 22.3 ± 5.8 | 21.2 ± 6.2 |
| CDR, global | 1.0 ± 0.6 | 0.9 ± 0.6 | 1.3 ± 0.8 | 0.9 ± 0.4 | 1.2 ± 0.7 | 1.0 ± 0.6 | 1.1 ± 0.7 |
| CDR, box score | 5.6 ± 3.5 | 5.2 ± 3.3 | 6.9 ± 4.5 | 5.1 ± 2.6 | 6.6 ± 4.8 | 5.7 ± 3.4 | 5.5 ± 3.9 |
| CDR+NACC FTLD, global | 1.3 ± 0.7 | 1.2 ± 0.7 | 1.6 ± 0.7 | 1.2 ± 0.5 | 1.4 ± 0.7 | 1.3 ± 0.7 | 1.3 ± 0.7 |
| CDR+NACC FTLD, box score | 7.5 ± 4.2 | 6.8 ± 3.7 | 9.1 ± 5.4 | 6.8 ± 3.4 | 9.3 ± 5.5 | 7.5 ± 4.0 | 7.6 ± 4.6 |
| Clinical symptoms | |||||||
| Parkinsonism, No., % | 36, 64% | 19, 70% | 7, 78% | 7, 50% | 3, 50% | 25, 64% | 11, 65% |
| RBD, No., % | 9, 16% | 5, 19% | 2, 22% | 1, 7% | 1, 17% | 5, 13% | 4, 24% |
| Dysautonomia, No., % | 5, 10% | 4, 17% | 1, 11% | 0, 0% | 0, 0% | 4, 11% | 1, 6% |
| Fluctuations, No., % | 9, 17% | 3, 13% | 3, 33% | 3, 21% | 0, 0% | 6, 17% | 3, 18% |
| Anxiety, No., % | 20, 36% | 8, 30% | 5, 55% | 6, 43% | 1,17% | 13, 33% | 7, 41% |
| Depression, No., % | 23, 41% | 11, 41% | 4, 44% | 6, 43% | 2, 33% | 17, 44% | 6, 35% |
| Hallucinations, No., % | 6, 11% | 0, 0% | 4, 44% | 1, 7% | 1, 17% | 1, 3% * | 5, 29% * |
| Neuropathology | |||||||
| Brain weight, g | 1132 ± 143 | 1111 ± 135 | 1229 ± 145 † | 1114 ± 143 | 1121 ± 143 | 1105 ± 142 * | 1192 ± 129 * |
| ADNC | 1.8 ± 1.2 | 1.5 ± 1.2 | 2.2 ± 1.2 | 2.7 ± 0.8 † | 0.8 ± 0.4 | 1.7 ± 1.2 | 2.2 ± 1.1 |
| AD pathology, No., % ** | 27, 48% | 9, 33% | 6, 66% | 12, 85% † | 0, 0% | 16, 41% | 11, 65% |
| FTLD‐tau, No., % | 20, 36% | 12, 44% | 3, 33% | 1, 7% † | 4, 67% | 16, 41% | 4, 24% |
| FTLD‐TDP, No., % | 13, 23% | 7, 26% | 0, 0% | 4, 29% | 2, 33% | 11, 28% | 2, 12% |
Abbreviations: LBD, Lewy body disease; CSF, cerebrospinal fluid; MMSE, Mini Mental State Examination; CDR, Clinical Dementia Rating Scale; NACC, National Alzheimer's Coordinating Center; FTLD, frontotemporal lobar degeneration; RBD, rapid eye movement sleep behavior disorder; ADNC, Alzheimer's disease neuropathological change (0 = none, 1 = low, 2 = intermediate, 3 = high); TDP, TAR DNA‐binding protein.
†
Significantly different from non‐LBD (p < 0.05).
*
Significantly different from each other (p < 0.05).
**
Presence of AD neuropathology defined as ADNC of intermediate or high